Metformin and Healthspan: Does It Reduce Diseases of Aging?

1. Metformin use was associated with lower all-cause mortality

Across the included evidence, metformin use in people with type 2 diabetes was associated with a lower risk of death from any cause.

This is particularly relevant to longevity research because all-cause mortality is a clinically meaningful outcome rather than a laboratory marker or proposed biological mechanism.

However, all of the evidence was observational.

The studies therefore show an association between metformin use and lower mortality. They cannot establish that metformin itself caused people to live longer.

2. Metformin use was associated with lower incidence of cardiovascular disease

The review also found an association between metformin use and a lower incidence of cardiovascular disease.

Cardiovascular disease is a major cause of morbidity, disability and mortality with increasing age. Preventing or delaying cardiovascular disease could therefore make an important contribution to healthspan.

However, only three included studies investigated cardiovascular disease, and all were observational.

The finding should therefore be interpreted as a potentially important association rather than proof that metformin itself prevents cardiovascular disease.

3. Metformin use was associated with lower incidence of dementia

Four studies investigated dementia.

Overall, metformin use in people with type 2 diabetes was associated with a lower incidence of dementia.

Preservation of cognitive health is an important component of healthy aging, making this another potentially important finding.

However, observational studies cannot completely account for differences between people who receive metformin and comparison groups.

The review therefore does not establish that metformin directly protects the brain or prevents dementia.

4. Cancer findings were inconsistent

Cancer represented the largest group of studies, with 17 included publications.

The findings varied according to cancer type.

Metformin use was associated with a lower risk of prostate cancer, but results for other cancers were inconsistent and remained inconclusive.

The review therefore does not provide evidence for a general cancer-preventive effect of metformin.

5. No randomized controlled trials met the inclusion criteria

This is the most important limitation when interpreting the findings.

The researchers searched for both randomized controlled trials and cohort studies. However, all 27 eligible studies were observational cohorts.

No randomized controlled trial met the inclusion criteria.

This means that causality cannot be established.

People receiving metformin may differ from comparison groups in their metabolic health, severity and duration of diabetes, other medications, healthcare use and additional characteristics that could influence long-term outcomes.

The studies were considered high quality according to their Newcastle–Ottawa Scale scores, but this does not remove the fundamental limitations of observational research.

In addition, differences between studies were substantial enough that the researchers could not perform a meta-analysis.

Longevity is not determined only by whether a treatment can directly alter biological aging.

Preventing or delaying major chronic diseases can also help people remain healthier for longer.

This is where metformin may have particular relevance.

In people with type 2 diabetes, metformin use was associated with favorable outcomes across several areas that strongly influence healthspan: all-cause mortality, cardiovascular disease and dementia.

These findings support the possibility that metformin could contribute indirectly to healthier aging in people with type 2 diabetes.

But that conclusion has clear boundaries.

First, association does not establish causation. The review cannot determine how much of the observed benefit was caused by metformin itself.

Second, the evidence applies to people with type 2 diabetes. It cannot establish a longevity benefit for metabolically healthy individuals taking metformin as a preventive anti-aging medication.

Third, the review provides no direct evidence that metformin slows biological aging. It assessed healthspan-related clinical outcomes rather than the aging process itself.

Metformin therefore has a plausible and clinically relevant place in the discussion of healthy aging, particularly in people with metabolic disease. The stronger claim — that metformin is a proven anti-aging drug for healthy people — is not supported by this review.

In people with type 2 diabetes, metformin use was associated with lower all-cause mortality and lower incidence of cardiovascular disease and dementia.

These outcomes are clinically relevant to healthy aging because they can influence both lifespan and the number of years lived without major chronic disease.

This raises an important possibility: metformin may contribute indirectly to healthier aging in people with type 2 diabetes by being associated with better outcomes in diseases that commonly reduce healthspan.

However, this review cannot establish that metformin itself caused these benefits. All 27 included studies were observational, and no randomized controlled trial met the inclusion criteria.

The population is equally important.

Every included study involved people with type 2 diabetes. The findings therefore cannot establish that metabolically healthy people would gain similar benefits from taking metformin specifically for longevity.

Finally, the review investigated mortality and diseases associated with aging. It did not test whether metformin directly slows the underlying biological processes of aging.